Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.53 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.53 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.53 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23977899 | 0.85 | CSNK2A1 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL29964021 | 0.85 | CSNK2A1 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL30806787 | 0.80 | ALDH1A1 (0.56) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL21541889 | 0.78 | MAPKAPK2 (0.47) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL9228663 | 0.77 | MAPKAPK2 (0.50) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL30637065 | 0.77 | MAPKAPK2 (0.50) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL7757513 | 0.77 | RPS6KA3 (0.64) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL31214307 | 0.76 | RPS6KA3 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL2948093 | 0.76 | MAPKAPK2 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 | |
| SCHEMBL706525 | 0.76 | MAPKAPK2 (0.53) | MAPKAPK2RPS6KA3CSNK2A1PLK3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0520024-B1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1996-06-19 | — | — | EP | claimed |
| CN-108752325-B | Preparation method of 3-oxyalkyl quinoxaline-2 (1H) -ketone compound | 曲阜师范大学 | 2021-03-23 | — | — | CN | disclosed |
| CN-105037425-A | Synthetic method for 2(1H)-quinoxalinone C-3 site phosphate compound | UNIV HUAQIAO | 2015-11-11 | — | — | CN | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | GOODMAN KRISTA B | 2010-10-07 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749998-B2 | Morpholinyl and pyrrolidinyl analogs | GLAXOSMITHKLINE LLC (US) | 2010-07-06 | — | — | US | disclosed |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | SMITHKLINE BEECHAM CORPORATION | 2009-11-05 | — | — | US | disclosed |
| EP-0520024-B1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK AS (DK) | 1996-06-19 | — | — | EP | disclosed |
| US-5514680-A | ANTICONVULSANTS WITH 5,6,7-TRISUBSTITUTED-1,4-DIHYDROQUINOXALINE-2,3-DIONE | THE STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0647137-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000124-A1 | GLYCINE RECEPTOR ANTAGONISTS AND THE USE THEREOF | WEBER ECKARD (US) | 1994-01-06 | — | — | WO | disclosed |
| US-5196421-A | Treatment of neurological disorders | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0520024-A1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE. | NOVO NORDISK AS (DK) | 1992-12-30 | — | — | EP | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| US-5166155-A | Neurological or psychiatric diseases | NOVO NORDISK A/S (DK) | 1992-11-24 | — | — | US | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1991013878-A1 | QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1991-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256130-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | MAPKAPK2 1501/4885RPS6KA3 3580/4885CSNK2A1 3976/4885 |
| US-20090275571-A1 | MORPHOLINYL AND PYRROLIDINYL ANALOGS | UTS2R, AVPR2, VIPR2 | MAPKAPK2 1501/4885RPS6KA3 3580/4885CSNK2A1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.